Dr. Falk Pharma acquires spinout Kynos Therapeutics to develop its novel KMO inhibitors for acute pancreatitis
October 29, 2024
29 October 2024, Dr. Falk Pharma GmbH today announced completion of the acquisition of Kynos Therapeutics Ltd., a clinical stage biopharmaceutical company focusing on the